GERIATRIC THERAPEUTICS
Editors: Michael Woodward, Director, Aged and Residential Care Services, Stephen Campbell, Consultant Geriatrician,
Rohan Elliott, Clinical Pharmacist, Graeme Vernon, Drug Information Pharmacist, Francine Tanner, Clinical Pharmacist,
Austin Health; Robyn Saunders, Consultant Pharmacist, Victoria.
Psychotropic Medication Use in Older People
Malcolm J Hopwood
ABSTRACT
Older people have high rates of mental health disorders such as
mood and anxiety disorders, bipolar affective disorder, psychotic
disorders, and dementia. All of these disorders are associated
with significant morbidity and mortality and have been historically
under-recognised and under-treated. Recent advances in
psychopharmacology have brought great benefit to many young
patients with these conditions where they are supported by a
clear evidence base. To date, this evidence base has been
incompletely developed for older people leaving the prescriber
with many difficult decisions. There is moderate and growing
evidence supporting the use of antidepressants in this population.
The use of mood stabilisers and antipsychotics for indications
other than the behavioural and psychological symptoms of
dementia currently occurs in the absence of effective evidence.
J Pharm Pract Res 2007; 37: 153-6.
INTRODUCTION
Mental health disorders are a leading cause of disability in older
people in our population. They also contribute to increased
mortality, either directly via suicide or indirectly by contributing
to poor control of comorbid physical health conditions.
Management of mental health disorders in older people
continues to be initially dependent upon the individual presenting
to a health professional and that professional making an accurate
diagnosis. The professional requires the ability to elicit symptoms
and signs of mental health disorder and then use this information
to make an appropriate hierarchical diagnosis. The reliability
of mental health diagnosis has improved considerably over
recent decades with the introduction of standardised diagnostic
systems such as the American Psychiatric Association’s DSMIV. Clinicians need to be aware of these diagnostic systems as
most of the available evidence relating to the use of mental
health interventions is based on samples defined using these
standard diagnostic criteria. It is also important to acknowledge
the clinical axiom that mental health disorders are more likely
to be comorbid with another mental health condition. For
example, diagnostic evaluation of any elderly patient presenting
with depression should involve careful searching for common
comorbid diagnoses such as dementia, anxiety, substance abuse
or the possibility that this episode is part of a bipolar disorder.
Together with psychological, social and environmental
interventions, psychotropic drugs continue to form an important
part of the treatment of mental health disorders in the elderly.
Available evidence suggests that the rates of use of psychotropic
drugs in older people are high, particularly for those in residential
care settings.1 The evidence also suggests that there are
examples where the targeting and review of this treatment is of
unclear quality. This is of concern given the well documented
increased potential for adverse effects with most psychotropic
Malcolm J Hopwood, MD, FRANZCP, Director, Veterans’ Psychiatry Unit,
Director, Brain Disorders Program, Austin Health, Heidelberg West, Victoria
Address for correspondence: Associate Professor Malcolm Hopwood,
Veterans Psychiatry Unit, Austin Health, Heidelberg West Vic. 3081, Australia
E-mail: malcolm.hopwood@austin.org.au
Journal of Pharmacy Practice and Research Volume 37, No. 2, 2007
drugs when used in older people. Age-related changes in
adiposity, renal clearance, hepatic mass and blood flow, all
have the capacity to influence pharmacokinetics significantly,
leading to potential toxicity-related adverse effects of
psychotropic drugs.2 In their examination of changes in hepatic
cytochrome P450 subsystems (primary site of initial metabolism
of the majority of psychotropic drugs) in older people, Pollock
et al. described how the range of enzymatic activity increased
with age, likely broadening the effective dose range for any
given drug. However, if this variation is not clinically predictable,
the risk of inappropriate dosing is heightened.3 The important
issue of drug-drug interactions adds to the complexity. The
elderly are often on many medications for a range of conditions.
These issues strongly support the need for a clear,
evidence-based approach to psychopharmacology in older
people. This evidence base would enable informed choice of
drug for any set of individual symptoms and comorbidities. In
this review the focus will be on available data on the use of
psychotropic drugs specifically in older populations. The
primary focus will be on data relating to the use of the major
groups of psychotropic drugs—antidepressants, mood
stabilisers and antipsychotics in the treatment of the major
psychiatric conditions—depression, behavioural and
psychological symptoms of dementia (BPSD), anxiety
disorders, bipolar disorder and schizophrenia in the elderly.
ANTIDEPRESSANTS
Antidepressants remain the treatment of choice for mood
disorders in older people including major depression, dysthymia
or minor depression, and depression secondary to medical
conditions such as stroke or idiopathic Parkinson disease.4-6
Antidepressants may also be used to treat depression in
association with psychoses such as schizophrenia, prolonged
or severe depressive phases of bipolar affective disorder, and
mood symptoms seen with dementias such as Alzheimer’s
disease. Of growing relevance is the recognition of the role of
antidepressants in the treatment of anxiety disorders.
The cross-sectional prevalence of major depression in
those over 60 years has been estimated at 2 to 5%, with the
rate increasing considerably in those with comorbid physical
illness.7-9 Major depression in older people is clearly associated
with increased health care use and burden, in addition to the
increased morbidity and mortality mentioned above.10 Minor
depression may be a more common disorder, with lesser but
significant levels of associated morbidity and burden.11,12
A wide range of antidepressants are available in Australia.
All drugs registered for the indication of major depression are
implicitly registered for the treatment of major depression in
older people, seemingly independent of whether specific efficacy
data are available for that drug in older people. It is hoped that
this gap will be diminished by the recent policy of the European
regulatory authorities to encourage pre-registration trials of new
drugs in older people by facilitating early consideration of
applications that include such data in a general application. This
complements the policy of the US Food and Drug
Administration to similarly support applications containing
paediatric data.
153
A meta-analysis of all available placebo-controlled trials
on the treatment of major depression in older people suggests
an overall response rate of 60 to 70%, with placebo response
rates of 30%.13 This rate is comparable to that seen in young
adults with major depression. Similar response rates have also
been observed in trials examining the response of older people
with minor depression to antidepressants.6 There is a trend in
this evidence to suggest that time to response may be longer in
older patients.14,15 It should be noted that this observation could
be artefactual, resulting from trial design in older people involving
low starting doses and slow rates of dose escalation.
Active comparator trials offer the opportunity to examine
differences between antidepressants in terms of efficacy and
adverse effect profile. The number of trials available of this
nature is limited, with the largest number relating to comparisons
between tricyclic antidepressants (TCAs) and selective
serotonin reuptake inhibitors (SSRIs). In a recent meta-analysis
no difference was found between TCAs, SSRIs and other drugs
for which comparator data were available (predominantly the
monoamine oxidase inhibitors, venlafaxine, mirtazapine) in
overall efficacy.16 However, there were significant differences
between the groups in overall dropout rates during trials with
dropouts significantly more likely in those receiving TCAs (OR
vs SSRIs RR 1.24, 95%CI 1.05–1.46). This meta-analysis
revealed a predictable pattern of side effects, with anticholinergic
adverse effects most common with the TCAs, and
gastrointestinal adverse effects most common with the SSRIs.
It should be noted that the relatively small size of the data set
would not show up uncommon side effects that may be specific
to or more common in older people. It would also not show up
the issue of potential lethality in overdose, which is clearly a
more significant issue with the TCAs. Of some concern is
evidence suggesting an association of both the TCAs and SSRIs
with an increased risk of falls in older people.17 A range of
issues may contribute to this association, including the risk
associated with the mental health problem under treatment.
The clinical implications of these findings can be summarised
as supporting the role of antidepressants as efficacious treatment
for major and, probably minor, depression in older people.
Given the relative vulnerability of older patients to adverse
effects, the favourable adverse effect profile of newer drugs
such as the SSRIs means that they should probably be seen as
the treatment of initial choice.7
Another area for clinical consideration is the role of
antidepressants in the treatment of anxiety disorders in older
people. Along with the development of specific psychotherapies
such as cognitive behavioural therapy, the use of antidepressants
in the treatment of anxiety disorders such as generalised anxiety
disorder, panic disorder, obsessive compulsive disorder, posttraumatic stress disorder and social anxiety disorder in adults is
now associated with a large evidence base and a major reduction
in the suffering of many individuals. Sadly, the level of
investigation of the epidemiology of anxiety disorders in older
people is significantly less than in younger adults. There is a
clinical suspicion that they are significantly under-diagnosed in
older people. The limited available pharmacotherapeutic
treatment data suggest that the antidepressants are also effective
for treatment of anxiety disorders in older people.18,19 Further,
this body of evidence tends to support the conclusion that the
newer drugs, particularly the SSRIs are the treatment of choice
for most anxiety disorders in older people.20 This area is hopefully
one of significant future evaluation through rigorous trials.
Of equal significance to the emergence of the use of
antidepressants for anxiety disorders is the corresponding
reduction in the use of anxiolytics such as the benzodiazepines
154
for this set of indications. This change has been of such
significance that there is no new data on the use of anxiolytics in
older people available in the last decade. This may not yet be
reflected in decreased overall prescription rates for
benzodiazepines given the widespread use of these drugs in
older people for other indications, such as sleep difficulties.
MOOD STABILISERS
Mood stabilisers currently in use in Australia include lithium,
and the antiepileptics valproate and carbamazepine.
Lamotrigine, another antiepileptic is associated with a
considerable body of evidence suggesting efficacy in bipolar
affective disorder but is not registered for this indication in
Australia. A number of other drugs are currently under
investigation. Recently, a number of the atypical antipsychotics
have also gained the indication for treatment of acute episodes
of bipolar disorder and in the case of olanzapine maintenance
treatment of bipolar disorder. Controversy persists over the
role of antidepressants in the treatment of depressive phases of
bipolar affective disorder; recent data mainly obtained from
adult populations showed no benefit in their addition to standard
mood stabiliser treatment.21
Mood stabilisers are used primarily in the treatment of
bipolar disorder but are also used frequently in the treatment of
refractory unipolar major depression, schizoaffective disorder
and in the management of impulsivity associated with conditions
such as acquired brain injury.
Bipolar disorder has a prevalence rate of 1 to 2%, but it is
reported that 10% of all patients develop it after the age of 50
years. Further, bipolar disorder accounts for 5 to 19% of all
mood disorder presentations in older people and an estimated
5% of inpatient psychiatric admissions for older patients.22,23
Bipolar disorder in younger populations is associated with high
levels of disability and is frequently quoted as the psychiatric
disorder associated with the highest rate of suicide, with most
estimates of the lifetime risk between 12 and 20%.
Given the above it is extremely disappointing that there
are essentially no well designed trials that specifically examine
efficacy and tolerability of the mood stabilisers in older people
with bipolar disorder. Data extrapolated from those studies
involving mixed-aged subjects, case reports and clinical
experience suggest that these drugs may have equivalent efficacy
in the older group to that seen in younger patients, but that
conclusion can only be viewed as presumptive. In young
patients, lithium is considered the gold standard for efficacy in
the treatment of bipolar disorder. Lithium’s narrow therapeutic
index along with the influence of age-related deterioration in
renal excretion of lithium, make the drug more complex to use
in older patients. This may be successfully managed with the
use of dosages lower (and serum levels) than in younger patients,
together with more frequent monitoring of serum levels. Patients
and their carers also require very clear and repeated information
about the common drug-drug interactions associated with
lithium. The most important of these interactions are with drugs
that increase the renal excretion of lithium and thus can produce
toxicity. Such interactions can occur with diuretics (especially
the thiazides), non-steroidal anti-inflammatory drugs, ACE
inhibitors and metronidazole.
Sodium valproate would now be the other most widely
used mood stabiliser for bipolar disorder in some adult services,
but there is little specific evidence about its use in elderly patients
at this time. While serum level monitoring may be of less value
in determining efficacy than is the case for lithium, it remains a
useful guide in relation to toxicity and compliance.
Journal of Pharmacy Practice and Research Volume 37, No. 2, 2007
ANTIPSYCHOTICS
Antipsychotics available in Australia are broadly divided into
older typical antipsychotics and atypical antipsychotics. The
definition of atypicality is hotly debated but the essential
characteristic is the reduced risk of acute and chronic movement
disorders in comparison with the typical antipsychotics.24 This
difference is thought to relate to the centrality of the D2 receptor
blockade to the action of the typical antipsychotics.25 Because
of their relatively favourable adverse effect profile, atypical
antipsychotics have rapidly become the treatment of choice in
most situations, but recent evidence of possible specific adverse
effects in older people have thrown this into some doubt.
Antipsychotics are used for the treatment of psychotic disorders
such as schizophrenia, schizoaffective disorder, and severe
bipolar affective disorder. Of great relevance, they are also
used at times for the management of BPSD.
Recent interest in the use of antipsychotics in the elderly
has focused on their use in individuals with dementia.26 Five
per cent of people over the age of 65 years and 20% of those
over the age of 80 years have dementia, with more than 50%
of those diagnosed as suffering from BPSD. BPSD are clearly
distressing for the patient, their carers and are often significantly
predictive for the need for nursing home placement.27-29
Several studies have highlighted the efficacy of oral atypical
antipsychotics, risperidone and olanzapine in the treatment of
BPSD.30-35 Risperidone is currently the only drug listed and
funded for this indication in Australia. A recent meta-analysis
has addressed the issue of a possible increase in mortality
associated with the use of these drugs in the elderly with
dementia, mainly related to possible stroke-like events.36 A
recent Cochrane review concluded that while there was
evidence of efficacy, particularly for risperidone, the risks were
significant.37 At a clinical level this would suggest that the use of
atypical antipsychotics is best reserved for patients with more
severe BPSD, particularly those with clear psychotic
symptoms, severe agitation or impulsive aggression resulting in
a clear risk to the safety of the patient or others. This complex
area is reviewed in detail in several of the articles.38
By contrast, the level of investigation into the use of
antipsychotics in the treatment of schizophrenia in older people
is limited.37 Schizophrenia is a relatively common mental health
disorder with a lifetime incidence of approximately 1%. It is
estimated that the prevalence in individuals aged over 65 is 1
to 10 per 1000, with up to 12% of all nursing home residents
suffering from schizophrenia. The severe disability and mortality
associated with schizophrenia is well acknowledged. However,
a recent meta-analysis of studies examining the efficacy and
tolerability of atypical antipsychotics in older people with
schizophrenia revealed only three small short-term trials.39 The
authors noted that no significant conclusions could be drawn
and that further studies were urgently needed. This clearly leaves
the clinician treating the older patient with schizophrenia in a
difficult position, armed with information suggesting efficacy of
the atypical psychotics with a favourable adverse effect profile
in young patients with schizophrenia, but at the same time
awareness of the information from patients with BPSD
suggesting significant risk. Clinically, there remains little doubt
that elderly patients with schizophrenia require ongoing
antipsychotic treatment, as the risk of relapse remains high. It
also appears true clinically that overall the adverse effect profile
of the atypical psychotics is better than that of the older drugs
in this situation, but there is essentially no current evidence to
clearly back up this conclusion. It is also clinically noticeable
that while the recommendation from the manufacturers of most
atypical antipsychotics is that lower doses are often required in
Journal of Pharmacy Practice and Research Volume 37, No. 2, 2007
the elderly, in the treatment of schizophrenia specifically in the
elderly, doses required for optimal efficacy may be in the same
range as those used in younger adults.
CONCLUSION
While it is indisputably true that mental health disorders remain
a major cause of disability and mortality throughout the life
cycle, evidence on the use of psychopharmacological
interventions in the elderly with mental health issues remains
patchy at best. The clinician is frequently required to interpret
data from studies involving subjects of younger age and assume
that the conclusions are valid in older people. Clear theoretical
reasons exist to believe this may not be true, and in the case of
atypical antipsychotics, some reasons to be particularly
concerned that the situation may be very different. Further
research is desperately needed, particularly in the use of mood
stabilisers and antipsychotics for issues other than BPSD in the
elderly. Only when this research is available will the clinician be
in an adequate position to provide effective, evidence-based
care.
Competing interests: None declared.
References
1. Davison TE, McCabe MP, Mellor D, Ski C, George K, Moore KA. The
prevalence and recognition of major depression among low-level aged care
residents with and without cognitive impairment. Aging Ment Health 2007;
11: 82-8.
2. Greenblatt DJ, Harmatz JS, Shader RL. Clinical pharmacokinetics of
anxiolytics and hypnotics in the elderly: therapeutic considerations (Part 1).
Clin Pharmacokinet 1991; 21: 262-73.
3. Pollock BG, Perel JM, Altieri LP, Krishner M, Fasickza AL, Houck PR, et
al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.
Psychopharmacol Bull 1992; 28: 163-8.
4. Nelson JC. Diagnosing and treating depression in the elderly. J Clin
Psychiatry 2001; 62 (suppl. 24): 18-22.
5. Unutzer J. Diagnosis and treatment of older adults with depression in
primary care. Biol Psychiatry 2002; 52: 285-92.
6. Rocca P, Calvarese P, Faggiano F, Marchiaro L, Mathis F, Rivoira E, et al.
Citalopram versus sertraline in late-life nonmajor clinically significant depression:
a 1-year follow-up clinical trial. J Clin Psychiatry 2005; 66: 360-9.
7. Katona C. Depression in old age. Chichester: John Wiley and Sons; 1994.
8. Murphy E. Social origins of depression in old age. Br J Psychiatry 1982;
141: 135-42.
9. Ames D. Depressive disorders among elderly people in long-term institutional
care. Aust N Z J Psychiatry 1993; 27: 379-91.
10. Lebowitz BD, Pearsons JL, Schneider LS, Reynolds CF 3rd, Alexopoulos
GS, Bruce ML, et al. Diagnosis and treatment of depression in late life.
Consensus statement update. JAMA 1997; 278: 1186-90.
11. Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of
subsyndromal depressive symptoms and major depression in a sample of the
general population. Am J Psychiatry 1996; 153: 1411-17.
12. Lavretsky H, Kumar A. Clinically significant non-major depression: old
concepts, new insights. Am J Geriatr Psychiatry 2002; 10: 239-55.
13. Wilson K, Mottram P, Sivananthan A, Nightingale A. Antidepressants
versus placebo for the depressed elderly. Cochrane Database Syst Rev 2001.
14. Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E,
et al. Comparison in sertraline and nortriptyline in the treatment of major
depressive disorder in late life. Am J Psychiatry 2000; 157: 729-36.
15. Georgotas A, McCue RE. The additional benefit of extending antidepressant
trials past seven weeks in the depressed elderly. Int J Geriatr Psychiatry 1989;
4: 191-5.
16. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly.
Cochrane Database Syst Rev 2006.
17. French DD, Campbell R, Spehar A, Cunningham F, Foulis P. Outpatient
medications and hip fractures in the US: a national veterans study. Drugs
Aging 2005; 22: 877-85.
18. Flint AJ. Anxiety disorders in late life. Can Fam Physician 1999; 45: 26729.
19. Flint AJ. Generalised anxiety disorder in elderly patients: epidemiology,
diagnosis and treatment options. Drugs Aging 2005; 22: 101-14.
20. Flint AJ. Management of anxiety in late life. J Geriatr Psychiatry Neurol
1998; 11: 194-200.
21. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR,
Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar
depression. N Engl J Med 2007; 17: 1711-22.
22. Sajatovic M, Madhusoodanan S, Cooncea N. Managing bipolar disorder in
the elderly; defining the role of the newer agents. Drugs Aging 2005; 22: 39-54.
155
23. Aziz R, Lorberg B, Tampi RR. Treatments for late-life bipolar disorder. Am
J Geriatr Pharmacother 2006; 4: 347-64.
24. Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal
side-effects and new routes in schizophrenia research. Br J Psychiatry 1994;
164: 141-48.
25. Seeman P. Dopamine receptors and the dopamine hypothesis of
schizophrenia. Synapse 1987; 1: 133-52.
26. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Expert consensus
panel for using antipsychotic drugs in older patients. Using atypical
antipsychotics agents in older patients. J Clin Psychiatry 2004; 62 (suppl. 2):
1-41.
27. Gilley DW, Whalen ME, Wilson RS, Bennett DA. Hallucinations and
associated factors in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci
1991: 3: 371-6.
28. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family.
JAMA 1982; 248: 333-5.
29. Steele C, Rovner B, Chase BA, Folstein M. Psychiatric symptoms and
nursing home placements of patients with Alzheimer’s disease. Am J Psychiatry
1990; 147: 1049-51.
30. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et
al. A randomised placebo-controlled trial of risperidone for the treatment of
aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:
134-43.
31. DeDeyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL,
Eriksson S, et al. A randomised trial of risperidone, placebo, and haloperidol for
behavioural symptoms of dementia. Neurology 1999; 53: 946-55.
32. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M.
Comparison of risperidone and placebo for psychosis and behavioural
disturbances associated with dementia: a randomised, double-blind trial. J Clin
Psychiatry 1999; 60: 107-15.
33. Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in
reducing the emergence of psychosis among nursing home patients with
Alzheimer’s disease. J Clin Psychiatry 2001; 62: 34-40.
34. DeBerdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay
DP, et al. Comparison of olanzapine and risperidone in the treatment of
psychosis and associated behavioural disturbances in patients with dementia.
Am J Geriatr Psychiatry 2005; 13: 722-30.
35. De Deyn PP, Carrasco MM, DeBerdt W, Jeandel C, Hay DP, Feldman PD,
et al. Olanzapine versus placebo in the treatment of psychosis with or without
associated behavioural disturbances in patients with Alzheimer’s disease. Int J
Geriatr Psychiatry 2004; 19: 115-26.
36. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical
antipsychotic drug treatment for dementia: meta-analysis of randomised
placebo-controlled trials. JAMA 2005; 294: 1934-43.
37. Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and
psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006.
38. Woodward MC. Pharmacological treatment of challenging psychiatric
symptoms of dementia. J Pharm Pract Res 2005; 35: 228-39.
39. Marriott RG, Neil W, Waddingham S. Antipsychotic medication for elderly
people with schizophrenia (review). Cochrane Database Syst Rev 2006.
Submitted: 1 May 2007
Accepted after external review: 4 June 2007
156
Journal of Pharmacy Practice and Research Volume 37, No. 2, 2007